Vaccination programs for COVID-19 in ‘high-income countries’ (HICs) have benefited from their ability to secure contracts for preferential supply for several vaccines1. For the rest of the world, vaccine access is much less certain. Although leaders of G20 nations have pledged to ensure fair distribution of vaccines against COVID-19 worldwide, substantial challenges remain. The COVAX Facility aims to ensure that all countries will have equal access to doses and can compete with HICs to acquire doses, but some low-income countries may need to wait until at least 2022 before even the most vulnerable 20% of their populations are vaccinated.

Public opinion on global rollout of COVID-19 vaccines

Melegaro, Alessia;
2021

Abstract

Vaccination programs for COVID-19 in ‘high-income countries’ (HICs) have benefited from their ability to secure contracts for preferential supply for several vaccines1. For the rest of the world, vaccine access is much less certain. Although leaders of G20 nations have pledged to ensure fair distribution of vaccines against COVID-19 worldwide, substantial challenges remain. The COVAX Facility aims to ensure that all countries will have equal access to doses and can compete with HICs to acquire doses, but some low-income countries may need to wait until at least 2022 before even the most vulnerable 20% of their populations are vaccinated.
2021
2021
Clarke, Philip M.; Roope, Laurence S. J.; Loewen, Peter John; Bonnefon, Jean-Francois; Melegaro, Alessia; Friedman, Jorge; Violato, Mara; Barnett, Adr...espandi
File in questo prodotto:
File Dimensione Formato  
s41591-021-01322-9.pdf

non disponibili

Tipologia: Pdf editoriale (Publisher's layout)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 913.85 kB
Formato Adobe PDF
913.85 kB Adobe PDF   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11565/4040623
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 27
social impact